Jul 25, 2024
- Corporate
F. Hoffmann-La Roche Announces Half Year Results 2024
| Name of listed company: | Chugai Pharmaceutical Co., Ltd. |
| Code number: | 4519 (Prime Market of Tokyo Stock Exchange) |
| Head office: | 1-1, Nihonbashi-Muromachi 2-Chome, Chuo-ku, Tokyo |
| President & CEO: | Osamu Okuda |
| Inquiries to: | Kae Miyata |
| Head of Corporate Communications Dept. | |
| Tel:+81-(0)3-3273-0554 |
F. Hoffmann-La Roche Ltd. (hereafter “Roche”) [Head office: Basel, Switzerland. CEO: Thomas Schinecker] announced today its half year results 2024 (January 1 – June 30, 2024).
Roche Holding Ltd, a parent company of Roche and Chugai, owns 59.89% of Chugai’s issued shares (61.12% of voting rights) as of the end of June 2024.
Its investor updates and presentation materials can be found on its website (https://www.roche.com).
Chugai’s performance for the period of January 1 to June 30, 2024 is included in the announced Roche Group’s results.
| Investor Updates | Reporting |
Contact:
- For Media
- Chugai Pharmaceutical Co., Ltd.
- Media Relations Group, Corporate Communications Dept.,
- Hideki Sato
- Tel: +81-3-3273-0881
- E-mail: pr@chugai-pharm.co.jp
- For Investors
- Chugai Pharmaceutical Co., Ltd.
- Investor Relations Group, Corporate Communications Dept.,
- Takayuki Sakurai
- Tel: +81-3-3273-0554
- E-mail: ir@chugai-pharm.co.jp
